Thomas Niel

Thomas Niel

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Investing in Skillz Stock May be a Game That’s Impossible to Win

Instead of bottom fishing in SKLZ stock in the hope it gets bought out/the situation improves, you may want to just avoid it completely.

7 Meme Stocks Still Making a Lot of Noise

You may think the meme stocks trend is over, but these seven Reddit favorites are still receiving a lot of chatter online.

Is AT&T Stock a Value Stock or a Value Trap?

Even if AT&T's planned spinoff of WarnerMedia is only a partial success, it could still unlock a decent amount of value for T stockholders.

Scoop Up Alphabet Stock After Tech’s Big Sell-Off

It may be too early to 'buy the dip' with more richly priced tech names, but that's not the case here with GOOG stock.

Slowing Growth Means Game Over for Roblox Stock

Hold off on RBLX stock. Take a look instead at other opportunities among the hard-hit tech names.

Today’s Market Will Remain Unkind to Vinco Ventures Stock

With fear, uncertainty, and doubt overcoming many investors, now is the wrong time for them to own BBIG stock.

7 Drug Stocks to Consider After the Viatris Plunge

As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market.

Is CFVI Stock The Next DWAC? Not so Fast

CFVI stock could fall to single-digit prices, if the uncertainty around monetization plans for Rumble come back into focus.

Multiple Compression May be a Risk for Costco Stock

It may seem unsinkable, but a return to normal for interest rates may mean a slight drop in the forward valuation of COST stock.

Don’t Expect an Encore Performance From AMC Stock

Oddly enough, the Russia-Ukraine war could be what ends the meme madness in AMC stock as the "Ape Army" appears to be dwindling.